Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that it awarded inducement grants on July 22, 2024 to its Executive Vice President and Chief Financial Officer, Edward Dulac, under Intellia's 2024 Inducement Plan as a material inducement to employment.
2024年7月24日，馬薩諸塞州劍橋市（全球新聞線） - 表觀遺傳治療公司Intellia Therapeutics，Inc.（納斯達克：NTLA）是一家領先的臨床試驗基因編輯公司，專注於用基於CRISPR的治療方法改變醫學，今天宣佈，作爲僱用的重要誘因，在Intellia的2024誘因計劃下，於2024年7月22日向其執行副總裁兼首席財務官Edward Dulac授予誘因股份獎勵。
The inducement grants consisted of non-qualified stock options to purchase 96,219 shares of Intellia's common stock with an exercise price of $25.33 per share, the closing price of Intellia's common stock as reported by Nasdaq on July 22, 2024, with 33% of the options underlying the option award vesting on the first anniversary of the grant date and the remainder vesting monthly thereafter until fully vested on the third anniversary of the grant date; time-based restricted stock units ("RSUs") for 66,324 shares of Intellia's common stock, with one-third of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date; performance-based RSUs for 33,162 shares of Intellia's common stock, with vesting criteria linked directly to Intellia's total stockholder return over a three-year period compared to the companies comprising the Nasdaq Biotechnology Index at the beginning of the performance period; and performance-based RSUs for 30,000 shares (at target) of Intellia's common stock, with vesting criteria linked directly to certain development milestones over a three-year period.
誘因獎勵包括非合格股票期權，可以購買96,219股Intellia普通股，行權價格爲每股25.33美元，這是納斯達克於2024年7月22日報告的Intellia普通股收盤價，這些期權獎勵的底層期權中的33%在授予日一週年時便行權，其餘部分在第三週年慶祝日之前每月解除限制; 時限限制的股票單元(“RSUs”)，可獲得Intellia普通股的66,324股，其中RSU獎勵底層股票的份額的三分之一在授予日的每個三連續週年慶祝日上行使; 性能單元RSUs，可獲得33,162股Intellia普通股，解除限制的條件直接與Intellia三年期間的總股東回報相比較，該期間的公司包括納斯達克生物技術指數的組成部分; 以及績效RSUs，爲Intellia普通股的30,000股(在目標的情況下)，解除限制的條件直接與三年期間的某些開發里程碑相連。
All equity vesting is subject to Mr. Dulac's continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
所有股權解除限制均取決於杜拉克先生作爲Intellia僱員的繼續服務直到適用的解除限制日期。
All of the above-described awards were granted outside of Intellia's stockholder-approved equity incentive plans pursuant to Intellia's 2024 Inducement Plan, which was adopted by the board of directors in June 2024. The awards were approved by a majority of the independent directors of Intellia's board of directors as a material inducement to Mr. Dulac's entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
所有上述獎勵都是根據Intellia的2024年誘因計劃授予的，該計劃於2024年6月由董事會採納。這些獎勵得到了Intellia董事會獨立董事的多數批准，作爲杜拉克先生進入Intellia僱傭的重要誘因，符合納斯達克上市規則5635(c)(4)的規定。
About Intellia Therapeutics
關於Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company's in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia's ex vivo programs use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Therapeutics, Inc.（納斯達克: NTLA)是一家領先的臨床前基因編輯公司，致力於用基於CRISPR的治療方法改變醫學的未來。該公司的體內項目利用CRISPR技術，直接在人體內精確地編輯導致疾病的基因。Intellia的體外項目則使用CRISPR技術，在人體外工程化處理人體細胞，以治療癌症和自身免疫性疾病。Intellia在深入的科學、技術和臨床開發經驗以及其人才方面都樹立了新藥標準。爲了充分利用基因編輯的全部潛力，Intellia繼續擴展其基於CRISPR的平台的能力，推出新的編輯和遞送技術。欲了解更多信息，請訪問intelliatx.com並關注我們@intelliatx。
Intellia Contacts:
Intellia聯繫人：
Investors:
Ian Karp
Senior Vice President, Investor Relations and Corporate Communications
ian.karp@intelliatx.com
投資者：
Ian Karp
高級副總裁，投資者關係和企業傳播
ian.karp@intelliatx.com
Lina Li
Senior Director, Investor Relations and Corporate Communications
lina.li@intelliatx.com
李娜
高級總監，投資者關係和企業傳播
lina.li@intelliatx.com
Source: Intellia Therapeutics, Inc.
來源：Intellia Therapeutics，Inc。
譯文內容由第三人軟體翻譯。